Successful Treatment of Type B Insulin Resistance With Rituximab | Zendy

Emmanouil-Dimitrios Manikas | Zendy; Iona Isaac | Zendy; Robert K. Semple | Zendy; Rana Malek | Zendy; Dagmar Führer | Zendy; Lars C. Moeller | Zendy; Dagmar FührerSakel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Successful Treatment of Type B Insulin Resistance With Rituximab

Author(s) -

Emmanouil-Dimitrios Manikas,

Iona Isaac,

Robert K. Semple,

Rana Malek,

Dagmar Führer,

Lars C. Moeller,

Dagmar FührerSakel

Publication year - 2015

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2014-3552

Subject(s) - insulin resistance , medicine , rituximab , insulin , endocrinology , cyclophosphamide , type 2 diabetes , plasmapheresis , diabetes mellitus , chemotherapy , immunology , antibody , lymphoma

Type B insulin resistance is a very rare disease caused by autoantibodies against the insulin receptor. The mortality of type B insulin resistance is high (>50%), and management of this disease is not yet standardized. We report the successful treatment of a patient with type B insulin resistance with rituximab, cyclophosphamide, and prednisone.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research